Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic.
暂无分享,去创建一个
Kenneth K C Man | C. Reich | Yi Chai | Hao Luo | W. Lau | Dong Yun Lee | C. O. Torre | S. Fortin | D. Kern | I. Wong | C. Chui | R. Park | Jae-Won Jang | Kathy Y. Liu | R. Howard | Can Yin | Jing Li | Xiaoyu Lin
[1] M. Smalbrugge,et al. The course of neuropsychiatric symptoms and psychotropic drug use in Dutch nursing home patients with dementia during the first wave of COVID‐19: A longitudinal cohort study , 2022, International journal of geriatric psychiatry.
[2] T. Taverner,et al. Decreased renal function is associated with incident dementia: An IMRD‐THIN retrospective cohort study in the UK , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[3] I. Vahia,et al. Impact of COVID-19 restrictions on behavioural and psychological symptoms in home-dwelling people with dementia: a prospective cohort study (PAN.DEM) , 2022, BMJ Open.
[4] H. Oh,et al. Containment, Health, and Social Policies in the Time of COVID-19 - Patterns and Determinants of Initial Reponses from Spring 2020 Across 120 Countries. , 2021, Health policy and planning.
[5] M. Suchard,et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study , 2021, BMJ.
[6] Andrew E. Williams,et al. Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience , 2021, Pediatrics.
[7] K. Verhamme,et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 20.6 million people in six European countries , 2021, medRxiv.
[8] D. Madigan,et al. Drawing Reproducible Conclusions from Observational Clinical Data with OHDSI , 2021, Yearbook of Medical Informatics.
[9] S. Majumdar,et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker) , 2021, Nature Human Behaviour.
[10] G. Lip,et al. Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications , 2021, Pharmacological Research.
[11] C. Chew‐Graham,et al. Effects of the COVID-19 pandemic on primary care-recorded mental illness and self-harm episodes in the UK: a population-based cohort study , 2021, The Lancet. Public health.
[12] L. Schneider,et al. Antipsychotic prescribing to people with dementia during COVID-19 , 2020, The Lancet Neurology.
[13] R. Allegri,et al. COVID-19 Epidemic in Argentina: Worsening of Behavioral Symptoms in Elderly Subjects With Dementia Living in the Community , 2020, Frontiers in Psychiatry.
[14] Naaheed Mukadam,et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.
[15] Andrew K. Przybylski,et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science , 2020, The Lancet Psychiatry.
[16] B. Pfefferbaum,et al. Mental Health and the Covid-19 Pandemic. , 2020, The New England journal of medicine.
[17] José Luis Molinuevo,et al. Dementia care during COVID-19 , 2020, The Lancet.
[18] J. O'Brien,et al. Dementia: assessment, management and support: summary of updated NICE guidance , 2018, British Medical Journal.
[19] A. Gasparrini,et al. Interrupted time series regression for the evaluation of public health interventions: a tutorial , 2016, International journal of epidemiology.
[20] G. Waldemar,et al. Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors. , 2017, Journal of Alzheimer's disease : JAD.
[21] C. Sudlow,et al. Comparison of dementia recorded in routinely collected hospital admission data in England with dementia recorded in primary care , 2016, Emerging Themes in Epidemiology.
[22] Rae Woong Park,et al. Characterizing treatment pathways at scale using the OHDSI network , 2016, Proceedings of the National Academy of Sciences.
[23] B. Sarfati,et al. Validity And Limitations Of The Longitudinal Patient Database France For Use In Pharmacoepidemiological And Pharmacoeconomics Studies , 2015 .
[24] Yu-Chuan Li,et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers , 2015, MedInfo.
[25] L. Schneider,et al. Risk of mortality among individual antipsychotics in patients with dementia. , 2012, The American journal of psychiatry.
[26] Truls Østbye,et al. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. , 2009, Journal of Alzheimer's disease : JAD.